• Explore /
  • Poster
  • / A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818).

A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818).

Abstract Poster

Authors

null

Takayuki Yoshino

Department of Gastroenterology and Gastrointestina

Takayuki Yoshino , Kentaro Yamazaki , Motoki Yoshida , Mark Rutstein , Naoto Yoshizuka , Atsushi Ohtsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01286818

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr591)

DOI

10.1200/jco.2013.31.4_suppl.591

Abstract #

591

Poster Bd #

E39

Abstract Disclosures

Similar Posters

First Author: Axel Grothey

First Author: T. Hansen

First Author: Heinz-Josef Lenz

First Author: Xin Qu